Cessatech reports last patient dosed in pharmacokinetic trial in children of lead candidate
· Clinical trial 0206 will investigate the pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures. · Primary aim is to obtain pharmacokinetic data from this age group and to demonstrate that CT001 is feasible as premedication in children undergoing a painful procedure. · Topline results are anticipated by the end of Q3 2022Cessatech A/S announces that the pharmacokinetic trial (0206) in children has finalised recruitment of all planned patients. The trial is designed as a non-randomised, open-label study in 25 children aged 1-17 years needing